ClinicalTrials.gg
RecruitingNCT06867354WEAN OBESEUpdated Jun 5, 2025

Prevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients

An observational study in Obesity, Obesity With Complications and Weaning From Mechanical Ventilation in Care Unit, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
17th of 20
80 · median 175
Started
2025
with 5 others
Observational
20 of 58
6 open now
Primary completion
2027-03
later than 5 of 15 live
Registered
53rd of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 17th largest by planned enrollment of the 20 observational ones that give a count, is one of 6 that started in 2025, is one of 20 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 53rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

ICU patients encounter numerous discomforts, with dyspnea (the sensation of breathlessness) being among the most distressing and impactful. Unlike pain, dyspnea in ICU settings has historically received limited attention, despite its severe psychological impact. ICU clinicians often use assessment tools like the simple numerical dyspnea scale (Dyspnea-VAS) and the Respiratory Distress Observation Scale (MV-RDOS) to measure dyspnea. These scales are also utilized during the weaning process, an essential phase when patients attempt to breathe independently without ventilator assistance. Weaning is crucial for ICU patients, as delayed or unsuccessful extubation increases the risk of complications and mortality.

Obese ICU patients, often admitted due to respiratory failure, present unique challenges due to physiological changes in the respiratory system, such as reduced functional residual capacity and decreased lung compliance. These factors contribute to an increased likelihood of dyspnea and weaning complications. Approximately 50% of obese ICU patients require mechanical ventilation, and once ventilated, obese patients exhibit an elevated risk for dyspnea and ventilator weaning failure.

Understanding the prevalence, causes, and consequences of dyspnea and failure in weaning process in obese ICU patients is critical. In this study, the aim is to compare obese patients with non-obese patients in terms of dyspnea prevalence, causes and consequences as weaning failure prevalence, causes and consequences.

Read the detailed description

Research Justification:

ICU patients face numerous sources of discomfort, among which dyspnea- the subjective sensation of breathlessness-stands out as especially distressing. Unlike pain, dyspnea has historically received limited attention, despite its severe psychological impact, including feelings of panic and death anxiety. Dyspnea integrates both physical and psychological suffering, often leading patients to report it as one of the most unbearable experiences, highlighting its significance for ICU caregivers. The subjective nature of dyspnea presents a diagnostic challenge, as it may occur without visible respiratory distress, which complicates detection and management. Dyspnea arises from complex mechanisms, including increased respiratory muscle load from airway resistance or thoracic compliance reduction. Additionally, dyspnea can be induced by an increased need for air due to elevated carbon dioxide levels or reduced oxygen levels, triggering chemoreceptor responses.

For ICU patients mechanically ventilated, the prevalence of dyspnea has been reported between 34 and 47%. Dyspnea assessment tools, such as the Dyspnea-VAS (Visual Analog Scale) and the MV-RDOS (Respiratory Distress Observation Scale), are employed to measure dyspnea, even in intubated patients. These tools are especially useful during ventilator weaning, a critical phase when patients transition to spontaneous breathing. The weaning process, and particularly the spontaneous breathing test (SBT), a test during which the patient breath with the assistance of the ventilator, is critical. The failure of a SBT can increase mortality risk, length of mechanical ventilation and ICU stay.

In this study, the investigators focus in obesity. The growing prevalence of obesity adds an additional layer of complexity to ICU care, as obese patients present distinct challenges during ventilation and weaning. With physiological changes such as reduced lung compliance and increased airway resistance, obese patients have an elevated risk for dyspnea and ventilator weaning complications. Obesity prevalence surged during the COVID-19 pandemic until 40% of ICU patients, and today, up to 50% of obese ICU patients require mechanical ventilation.

In ICU obese patients and mechanically ventilated, there is no assessment of dyspnea, its determinants and its impact during ventilatory weaning. The pathophysiology of dyspnea and SBT failure is complex and primarily involves cardiac function and respiratory muscle function. Pulmonary edema is found in more than half of cases and is linked to the transition from a positive pressure ventilation regime to a negative pressure regime, which creates unfavorable loading conditions for the heart. The second cause described is diaphragmatic dysfunction characterized by atrophy of the respiratory muscles which can occur rapidly under mechanical ventilation. More recently, dyspnea has been described as a cause of SBT and extubation failure in its own right. Other causes have also been described such as intensive care neuropathy, iatrogenic causes (agitation, pain), anxiety, or even impaired ventilatory control.

In addition, the consequences of dyspnea and failure of SBT as well as their management are not described, such as the duration of mechanical ventilation, mortality, length of stay, intercurrent events such as new sepsis. or the administration of new treatments during the period from weaning to extubation.

Finally, the evolution of dyspnea after successful SBT and after extubation has never been described.

The prevalence, determinants and consequences of dyspnea and failure of the first SBT as well as their management in ICU patients with obesity have never been described. Likewise, improving the diagnostic performance of the clinical criteria for SBT failure with the contribution of dyspnea scales is a real challenge in these patients.

Research Design and Methodology:

Study Type: This is a descriptive, monocentric and comparative study.

03

Conditions studied

  • Obesity
  • Obesity With Complications
  • Weaning From Mechanical Ventilation in Care Unit
  • Dyspnea

Browse trials for

Keywords

  • Intensive Care Unit
  • Dyspnea
  • Mechanical Ventilation
  • Ventilatory Weaning
  • Obesity
  • Spontaneous Ventilation Test
  • Mortality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized in intensive care under mechanical ventilation for at least 48 hours, with or without obesity (BMI > 30 kg/m²).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients placed on mechanical ventilation for at least 48 hours
  • On spontaneous ventilation mode with inspiratory support (only possible ventilation mode during ventilation weaning) allowing a tidal volume > 6 mL/kg and a positive end-expiratory pressure set by the attending physician between 5 and 8 cmH2O
  • Decision by the attending physician to perform a spontaneous breathing trial (SBT) after verifying the prerequisites for weaning: resolution of the acute phase of the illness for which the patient is placed on invasive mechanical ventilation, low bronchial congestion, adequate cough, adequate oxygenation defined by SpO2 > 90% with FiO2 ≤ 40% and PEEP ≤ 8 cmH2O, respiratory rate ≤ 40 breaths/min, Ramsay sedation score \< 4, and stable cardiovascular state (heart rate ≤ 120 beats/min, systolic blood pressure ≤ 180 mmHg, and no or minimal vasopressors [norepinephrine \< 5 μg/kg/min])
  • After information,no opposition from the patient or the relative (if the patient is unable to express his non opposition) to participating in the research
  • Person affiliated with a social security regime or eligible
  • Patient with a > 30 kg/m² for those included in the case group (obesity)

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old
  • Pregnant or breastfeeding women
  • Patients for whom weaning is impossible (pre-existing neuromuscular disorders, cervical spinal cord lesions)
  • Patients for whom repeated dyspnea assessment is likely to be difficult (known history of cognitive or psychiatric disorders, delirium, Richmond Agitation-Sedation Scale score less than -2 or greater than 2)
  • Patients under legal protection measures (guardianship, curatorship)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with (BMI of ≥30 kg/m²) obesity
  • Patients without obesity
06

What researchers measure

Primary outcomes

  1. Presence or onset of dyspnea

    Presence or onset of dyspnea detected by the simple numerical dyspnea scale (Dyspnea-Visual Analog Scale VAS) from 0 to 10 cm , 0 means "no respiratory discomfort, no sensation of shortness of breath, no difficulty breathing" and 10 means "the worst imaginable respiratory discomfort, feeling of shortness of breath, inability to breathe" ≥ 4 before, and then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT. In order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.

    Time frame: Baseline

Secondary outcomes

  1. Measure of the affective component of dyspnea using the simple numerical dyspnea scale

    Measure of the affective component of dyspnea using the simple numerical dyspnea scale (Dyspnea-Visual Analog Scale VAS) from 0 to 10, 0 means "no anxiety related to dyspnea" and10 means "maximum anxiety related to dyspnea" before, and then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT, anxiety if Dyspnea-VAS \> 4, in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.

    Time frame: Baseline

  2. : Presence or onset of dyspnea detected by the Mechanical Ventilation - Respiratory Distress Observation Scale

    Presence or onset of dyspnea detected by the Mechanical Ventilation - Respiratory Distress Observation Scale (MV-RDOS) in mechanically ventilated in non-communicating patients from 0 to 5, 0 means no dyspnea and 5 means major dyspnea, before SBT then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT, dyspnea if MV-RDOS\> 2.6, in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.

    Time frame: Baseline

  3. Measure of Rapid Shallow Breathing Index (RSBI) (the ratio of respiratory frequency (f) to tidal volume (TV)) measured at 1 minute of SBT > 105 breaths/min/L.

    Measure of Rapid Shallow Breathing Index (RSBI) in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.

    Time frame: Baseline

  4. Measure of Pain with Visual Analog Scale (VAS) for pain from 1 to 100 mm (1 means no pain, 100 means major pain)

    Measure of pain in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity

    Time frame: Baseline

  5. Research of anxiety with Hospital Anxiety and Depression Scale (HADS) from 0 to 21, 0 means no anxiety, 21 means major anxiety, anxiety if HADS > 8

    Research of anxiety in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity

    Time frame: Baseline

  6. Number of patients with Respiratory Control Impairment:

    Number of patients with Respiratory Control Impairment in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity

    Time frame: Baseline

  7. Measure of the number of treatments added during SBT

    Measure of the number of treatments added during SBT in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity

    Time frame: Baseline

  8. Measure of the number of patients with early cessation of SBT at the patient's request for reasons unrelated to the validated clinical objective criteria for SBT failure;

    Measure of the number of patients with early cessation of SBT at the patient's request in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  9. Measure of number of SBT performed until extubation

    Measure of number of SBT performed until extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  10. Measure of the duration between the first SBT and the extubation

    Measure of the duration between the first SBT and the extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  11. Measure of the number of extubation failure defined by reintubation or death

    Measure of the number of extubation failure in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Within 7 days following extubation;

  12. Measure of the duration of invasive and non-invasive mechanical ventilation

    Measure of the duration of invasive and non-invasive mechanical ventilation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  13. Measure of the length of stay in the ICU

    Measure of the length of stay in the ICU in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  14. Measure of number of deaths in ICU

    Measure of number of deaths in ICU in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  15. Measure of number of intercurrent events between the clinical outcome of the first SBT and extubation

    Measure of number of intercurrent events between the clinical outcome of the first SBT and extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  16. Research of the number of treatments administered between the first SBT and extubation

    Research of the number of treatments administered between the first SBT and extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.

    Time frame: Length of the ICU hospitalization (2 months maximum)

  17. Description of the prevalence of first SBT failure in ICU patients and affected (case) or not (control) by obesity.

    SBT failure defined by the appearance of at least one of the following objective criteria 1. Respiratory rate ≥ 35 breaths/min or an increase ≥ 50% compared to the baseline value, 2. SpO2 ≤ 90% or PaO2 ≤ 50 mmHg with FiO2 ≥ 50%, 3. PaCO2 \> 50 mmHg, 4. Heart rate ≥ 140 beats per minute, 5. New supraventricular or ventricular arrhythmia, 6. Systolic blood pressure \>180 or \< 90 mmHg, 7. Altered consciousness, 8. Signs of respiratory distress.

    Time frame: Baseline

  18. Measure of the number of patient with pulmonary edema during weaning

    Measure of the number of patient with pulmonary edema during weaning in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  19. Measure of the number of patient with acute myocardial ischemia (coronary syndrome with or without ST-segment elevation)

    Measure of the number of patient with acute myocardial ischemia (coronary syndrome with or without ST-segment elevation):in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  20. Measure of the number of patient with respiratory muscle impairment and diaphragmatic dysfunction

    Measure of the number of patient with respiratory muscle impairment and diaphragmatic dysfunction in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  21. Measure of the number of patient with critical illness neuromyopathy

    Measure of the number of patient with critical illness neuromyopathy in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  22. Measure of the number of patient with dyspnea

    Measure of the number of patient with dyspnea in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  23. Measure of the number of patient with anxiety with Hospital Anxiety and Depression Scale (HADS) from 0 to 21, 0 means no anxiety, 21 means major anxiety, anxiety if HADS > 8

    Measure of the number of Measure of the number of patient with anxiety in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  24. Measure of the number of patient with respiratory control impairment:

    Measure of the number of patient with respiratory control impairment in order to describe the main causes of first SBT failure.

    Time frame: Baseline

  25. Measure of the number of patient with an early cessation of the SBT at the patient's request, outside of the validated clinical objective criteria for SBT

    Measure of the number of patient with an early cessation of the SBT at the patient's request, outside of the validated clinical objective criteria for SBT failure in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  26. Measure of Number of SBT performed until extubation

    Measure of the number of Number of SBT performed until extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  27. Measure of the Delay between the date of the first SBT and the date of extubation

    Measure of the delay between the date of the first SBT and the date of extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  28. Measure of the number of patient with an extubation failure defined by reintubation or death

    Measure of the number of patient with an extubation failure defined by reintubation or death within 7 days following extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  29. Measure of the duration of invasive and non-invasive mechanical ventilation

    Measure of the duration of invasive and non-invasive mechanical ventilation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  30. Measure of Duration of stay in the ICU

    Measure of Duration of stay in the ICU in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  31. Measure of the number of deaths in the ICU

    Measure of the number of deaths in the ICU in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  32. Measure of the number of Intercurrent events between the clinical outcome of the first SBT and extubation

    Measure of the number of Intercurrent events between the clinical outcome of the first SBT and extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation

    Time frame: Length of the ICU hospitalization (2 months maximum)

  33. Evaluate the contribution of combining the dyspnea scales measured during SBT with the usual clinical criteria to predict the diagnosis of SBT failure.

    Contribution of combining the dyspnea scales measured during SBT with the usual clinical criteria to predict the diagnosis of SBT failure (area under the curve, sensitivity, specificity, likelihood ratio).

    Time frame: Length of the ICU hospitalization (2 months maximum)

  34. Description of the evolution of dyspnea after extubation.

    Simple numeric rating scale for dyspnea (Dyspnea- Visual Analogic Scale (VAS)) and simple numeric rating scale assessing relief of dyspnea from 0 to 10 cm, 0 means 'no relief, no impression of improvement in breathlessness' and 10 means 'extraordinarily relieved,' performed 60 minutes after extubation and at 24 hours, dyspnea if Dyspnea-VAS \> 4

    Time frame: Length of the ICU hospitalization (2 months maximum)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 24 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Mar 10, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Mar 2027
CompletionEst.
May 2027
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06867354
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Mar 21, 2025
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 5, 2025

Study contacts

Alexandra BEURTON, Doctor
Contact
alexandra.beurton@aphp.fr
00 33 6 23 08 64 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion